Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Delta CRISPR Activation Plasmid (h): sc-400790-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Delta CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Delta CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Delta CRISPR Activation Plasmid (h) and Delta CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the DLL1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Delta Antibody (G-1): sc-377310
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Delta CRISPR Activation Plasmid (h) | sc-400790-ACT | 20 µg | $397.00 |
Human DLL1 encodes the Delta-like canonical Notch ligand 1 (Delta), a membrane-tethered ligand that engages NOTCH receptors to trigger proteolytic cleavage and release of the Notch intracellular domain, thereby regulating transcriptional programs that control cell fate decisions. DLL1-mediated Notch signaling is central to embryonic patterning, neurogenesis, somitogenesis, and maintenance of stem and progenitor cell compartments through modulation of differentiation, proliferation, and lateral inhibition. Altered DLL1/Notch axis activity has been linked to dysregulated tissue homeostasis and developmental disorders, and is frequently studied in contexts of aberrant signaling in cancer biology, angiogenesis, and immune cell differentiation. As a pathway node at the cell surface, DLL1 provides a tractable handle for dissecting juxtacrine signaling dynamics and downstream transcriptional responses.
Delta CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous DLL1 expression without altering the underlying DNA sequence.
Delta CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the DLL1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the DLL1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Delta expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native DLL1 locus and enabling the study of Delta-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Delta pathway restoration in tumor cells with silenced or reduced DLL1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.